Company intelligence
Compass Therapeutics Inc.
We are developing next-generation antibodies into transformative cancer therapies that improve patients’ lives.
About Compass Therapeutics Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. To learn more, visit www.compasstherapeutics.com
Verified activity
Signals from Compass Therapeutics Inc.
2 published signals
People
Compass Therapeutics Inc. introduced Sierra Tyrol as a new Team Compass member, Cemre Tokatli as an AP Specialist, and CMC as an Analytical Scientist I.
Reported by Compass Therapeutics Inc.
People
Compass Therapeutics Inc. welcomed Norma Alonzo Palma PhD as new VP and Head of Medical Affairs.
Reported by Compass Therapeutics Inc.